CD19 and non-Hodgkin lymphoma: At the clinical level, a second-generation academic trial (NCT05869279) is currently underway, expanding the evaluation of CARCIK-CD19 to a broader cohort of patients with R/R B-cell malignancies, including both B-ALL and non-Hodgkin lymphomas.